Salt Lake City – July 28th, 2025– Dômes Pharma, a global leader in veterinary ophthalmology solutions, is proud to announce its strategic alliance with Fear Free®, joining the Fear Free Preferred Product Program. This collaboration recognizes Dômes Pharma’s dedication to reducing stress in pets during eye care visits and highlights three of the company’s flagship products: Oculenis® – A preservative-free ocular barrier gel specifically designed for pets with corneal ulcers. Its BioHAnce™ technology enhances contact time and comfort, aiding healing while minimizing application frequency. Ocunovis® – A daily-use, preservative-free gel eye drop formulated to provide long-lasting hydration and relief for pets with dry eye or ocular surface disease, using the same advanced BioHAnce™ technology. Fluodrop™ – A sterile, single-use fluorescein ophthalmic solution used in diagnostic procedures to detect corneal defects and assess tear film breakup, offered in a...

With the acquisition of SentrX Animal Care, Inc. Dômes Pharma expands its global leadership in veterinary ophthalmology while creating a launching pad for its therapeutic product franchises in North America Pont-du-Château, August 16, 2023 – Dômes Pharma announces that it has finalized the acquisition of SentrX Animal Care, a US company based in Salt Lake City (Utah). SentrX develops and manufactures ophthalmology products based on its exclusive BioHAnce™ technology. BioHAnce™ is a patented crosslinked Hyaluronic Acid technology that enhances and accelerates natural healing, hydration and lubrication processes, while reducing the number of applications. The company, which has its own 2,000 m2 manufacturing plant, markets 3 products that have rapidly gained market share in the United States and Europe, notably in the UK, thanks to their effectiveness and ease of use. Less than a year after the opening...

We are pleased to announce the launch of Sentrx Eye Lube Pro, a solution to the demand for bulk lubrication during anesthetic procedures and a value-based approach to long-term lubrication needs. Taking advantage of our vertically integrated in-house manufacturing capabilities, Sentrx is able to produce a cost-effective bulk lubricant and pass the savings on to our veterinary customers.

  We are pleased to announce that Provet® has partnered with SentrxTM Animal Care as the exclusive distributor representing the patented crosslinked Hyaluronic Acid BioHAnce® brand of products in in Australia.Effective September 28, 2022 Sentrx ophthalmology products: Ocunovis™ BioHAnce™ Gel Eye Drops, Oculenis™ BioHAnce™ Ocular Barrier Gel will be available through Provet® to all authorized veterinary customers.All Sentrx products feature patented and clinically proven BioHAnce technology of which millions of doses have been sold globally to veterinarians*. This partnership allows veterinarians in Australia to prescribe the first and only formulation with cross-linked hyaluronic acid (HA). The cross-linking of BioHAnce provides the longest lasting ocular lubrication on the market. That promotes consistency of the tear film and enhances the eye’s ability to maintain hydration.“The benefits of topical hyaluronic acid (HA) use are well known within the global veterinary ophthalmology community, so it is...

SALT LAKE CITY, UT: Sentrx, an animal health company that transforms complex biotechnologies into easy-to-use care solutions that promote the long-term well-being of animals, today announced the formation of a US-based Ophthalmology Scientific and Medical Advisory Board (OSMAB) comprised of veterinary and scientific leaders in ophthalmology and clinical trial design. The board will be chaired by Chief Scientific Officer, Sarah Atzet, Ph.D. and will work closely with management to advance the company’s clinical pipeline development in the US and the utility of its platform BioHAnceTM technology, a patented molecular matrix of cross-linked hyaluronic acid (HA). “We’ve assembled a board of prestigious scientific and medical thought leaders to provide Sentrx with relevant and informed counsel in the months and years ahead, as we continue our research and application efforts and development of disruptive innovation in the veterinary...

Lubrication designed to last longer Get the pet owner preferred, glob-free product for dry eye in cats and dogs1 The only gel eye drops with patented BioHAnce™ crosslinked hyaluronic acid (HA) designed and tested for pets: Ocunovis™ Procare uniquely contains a patented hyaluronic acid polymer gel technology and is one of the only lubricating eye drops supported by masked clinical studies.1 Clinically proven: One of the only lubricating eye drops with masked clinical studies for pets proven to dramatically improve the symptoms associated with dry eye.1 Ocunovis™ ProCare acts as artificial tears but does not treat or cure the underlying causes of dry eye. Engineered for busy pet parents: Longer lasting lubrication means fewer applications and increased pet comfort. Pet owners are happier with Ocunovis ProCare*: 8 out of 10 dog owners rated Ocunovis™ as...

Sentrx™ Animal Care held a ribbon cutting event to celebrate the opening of its brand new 22,000 square foot manufacturing facility in Salt Lake City, Utah. The expansion into this larger new facility represents a major milestone for the Salt Lake City based company.

We are pleased to announce that EPiQ Animal Health has partnered with Sentrx™ Animal Care as the master distributor and commercial agency representing Ocunovis™ BioHAnce™ Gel Eye Drops, Oculenis™ BioHAnce™ Ocular Repair Gel, and Episanis™ BioHAnce™ Skin and Wound Gel.

EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced financial results for the three-month period